Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Protokinetix, Inc. PKTX

ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins). The AFGP is a compound produced by fish, insects, reptiles, bacteria, and plants that enable survival in freezing temperatures. The company also develops AFGP applications which include regenerative medicine issues including harvesting, processing, storage and transplanting cells, tissues and organs and treatments for chronic inflammatory conditions and diseases caused by stress factors, including UV radiation, oxidation, and cryopreservation and hydrogen peroxide.


Recent & Breaking News (OTCQB:PKTX)

ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants

Business Wire July 20, 2022

ProtoKinetix Announces Annual General Stockholder Meeting Will Be Held Virtually Only

Business Wire January 14, 2022

ProtoKinetix Announces Selection of AAGP® Candidate Formulations for Treatment of Dry Eye Disease

Business Wire November 23, 2021

ProtoKinetix and IQVIA Partner to Support Development of AAGP® Product in the Treatment of Ocular Conditions

Business Wire May 12, 2021

ProtoKinetix Announces the Resumption of Phase 1b Clinical Trials for the use of AAGP® Treated Islet Cells in the Treatment of Type 1 Diabetes

Business Wire April 22, 2021

ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat Dry Eye Disease & Ocular Inflammation with AAGP®

Business Wire April 14, 2021

Journal of Tissue Engineering and Regenerative Medicine Publishes Peer Reviewed Research Paper Establishing ProtoKinetix AAGP® Enhanced Stem Cell Vision Restoration

Business Wire April 7, 2021

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

Business Wire November 24, 2020

ProtoKinetix AAGP® Restores Vision in Blind Test Subjects

Business Wire September 15, 2020

Ammendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials Have Been Approved by Health Canada

Business Wire August 27, 2020

ProtoKinetix AAGP® Moves to Whole Organ Transplantation Testing

Business Wire August 14, 2020

Amendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada

Business Wire July 13, 2020

ProtoKinetix AAGP® Dry Eye Program Advancing

Business Wire July 7, 2020

ProtoKinetix AAGP® Exhibits Efficacy and Safety in Model of Dry Eye Disease

Business Wire April 6, 2020

ProtoKinetix Ready to Ship AAGP® to the University of Alberta for the Continuation of Phase 1 Human Trials

Business Wire March 24, 2020

ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease

Business Wire March 19, 2020

ProtoKinetix Announces Progress in the use of AAGP® in Cardiovascular Medicine

Business Wire February 19, 2020

ProtoKinetix Files for Patent Protection for the Use of AAGP® in Transplant Medicine

Business Wire February 11, 2020

ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial

Business Wire January 24, 2020

ProtoKinetix AAGP® Dry Eye Therapy Testing Results

Business Wire January 6, 2020